Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. - Wikidata - wikimedia - TriplyDB

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

http://www.wikidata.org/entity/Q33666297

about

Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 Parkinson's disease gene therapy: success by design meets failure by efficacy Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation.Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?The use of cerebrospinal fluid and neuropathologic studies in neuropsychiatry practice and research Decrease in plasma levels of α-synuclein is evident in patients with Parkinson's disease after elimination of heterophilic antibody interference Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis The Mental Status Examination in Patients With Suspected Dementia.Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson disease.Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects Blood-based biomarkers for Parkinson's disease The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease Hippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early Parkinson's disease: a cross-sectional study.Course of psychiatric symptoms and global cognition in early Parkinson disease.Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions Unbiased approaches to biomarker discovery in neurodegenerative diseases Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays.Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease.Comparison of two methods for the analysis of CSF Aβ and tau in the diagnosis of Alzheimer's disease CSF biomarkers and clinical progression of Parkinson disease.Cognition in movement disorders: where can we hope to be in ten years?A consensus in Korea regarding a protocol to reduce preanalytical sources of variability in the measurement of the cerebrospinal fluid biomarkers of Alzheimer's disease.Low-variance RNAs identify Parkinson's disease molecular signature in blood Total and Proteinase K-Resistant α-Synuclein Levels in Erythrocytes, Determined by their Ability to Bind Phospholipids, Associate with Parkinson's Disease.CSF proteins and resting-state functional connectivity in Parkinson disease.Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease.Olfactory impairment predicts cognitive decline in early Parkinson's disease.Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors.CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients.

P2860

Q26744782-8B579954-6EE7-4E5E-A468-03477356603C Q26801629-227629DC-1A97-4B13-9E31-3059E14E67AC Q26851325-C16C2647-15F3-48F8-B8E1-9075F59FBA80 Q26865234-DDCBFD9E-ED59-4BE7-AE99-90D7137DE461 Q27304608-B4C490AF-3D49-4E3F-B3A0-63F81EA24FB3 Q27311994-F56AAB01-05FB-4E56-B1A8-714EC8FE504D Q27314618-BF746C0F-3EEA-45E0-8228-0F13E6F49FE2 Q27331743-033E8943-8FBA-4870-B0D8-12E4864113F6 Q27686837-BBAD70E7-535A-4293-B9EC-A53E6139FFFB Q28072061-75012DCF-3BF8-4E6A-B066-5376D9410EF8 Q28076121-707F8A39-4C68-49FE-B571-BF5533732CAE Q28083203-63554357-66B5-48F7-92B6-A00E6D4D14A0 Q28088291-65A8CAC0-ED2E-4169-83E4-806C3943B3A5 Q28545821-9F1578C7-4CC0-467A-92B1-9AA6CD06414B Q28550937-2C3706EF-BC88-4BA6-B9EA-C14BFCDC15EE Q30659251-F8AF241F-0494-4DD0-AA14-71CFD6F37B40 Q30833019-5F470CB2-937F-4D3E-AFF2-AF0A2C7294DB Q33562433-F6AF294B-F0A9-4AB2-ADFB-85A658F5DE57 Q33574058-5BB093E1-D6A2-4C57-8638-79D75AA3AC3A Q33734084-59E570EC-604A-455B-8B76-909868D4B11B Q33804255-67A17FA8-E364-4A08-A7FC-6159A89F0DE8 Q33850971-02CFA1A1-C21E-4769-9C06-73D441B8F8CA Q33917300-F20DA6A3-4D4F-41BF-9F9B-16B44195E90B Q34198761-D71BD354-1D1C-4B4D-81E2-F577A097D510 Q34237637-4B68F877-8F59-4A1C-9D3C-64C87E30DF58 Q34625918-777B327D-2B8C-4D80-9E93-DD49D736DCD1 Q34627859-502ED0F0-F59F-49AA-8A3D-4651D12FB65E Q34714560-0F72BEF7-E485-4411-A50B-036E479C33EE Q34987497-73B98D6D-82B6-4BEE-959E-6BD37CEA59A1 Q35106542-D85B8A89-7C79-48D0-8DD9-07B498EAB1F6 Q35211553-16E05160-D0AD-486D-855F-F116B69D8D98 Q35291150-1699D02D-F33C-4ADA-AE90-986FD2EEA559 Q35630163-353687DC-0B0F-4F89-82FE-19CD9FE209ED Q35726772-9C8B66F3-6A13-404C-A24C-47EAB264AC3B Q35771985-D758B99B-4309-479B-9CAB-9829845E3C84 Q35772659-7E5AE978-EFAF-4C09-8306-7F04F9DA79A9 Q35938758-5E58CAFF-511A-4036-850F-130592DE2F7F Q35953962-4A623D5A-7B53-4707-B6B2-7E78BC5BCC55 Q36169215-0200F7B7-343C-42D6-8EDC-3DADD33BDA6C Q36172389-16DF297F-1D09-44AE-96A4-E9255F2CE7F4

P2860

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

http://www.wikidata.org/entity/Q33666297

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Association of cerebrospinal f ...... with early Parkinson disease.

@ast

Association of cerebrospinal f ...... with early Parkinson disease.

@en

type

label

Association of cerebrospinal f ...... with early Parkinson disease.

@ast

Association of cerebrospinal f ...... with early Parkinson disease.

@en

prefLabel

Association of cerebrospinal f ...... with early Parkinson disease.

@ast

Association of cerebrospinal f ...... with early Parkinson disease.

@en

P1433

Q33666297-75DF5E23-EE58-42C5-B91E-9FE8A74A48FD

P1476

Q33666297-F1994FCE-9C0D-4975-9E9E-3B2EFDECE507

P2093

Q33666297-08E786FE-BB74-4BBB-BF4C-4C0E337C4947

Q33666297-218DC0C1-6625-46ED-BDD5-89A0D9C696E3

Q33666297-28555856-52B9-45D0-9497-344E253C90D7

Q33666297-325D735F-E5F8-41D0-A488-6F00F5F59527

Q33666297-6E73F360-C2A7-48B1-8389-EABB7DDECC66

Q33666297-704F9990-AE62-45B5-89B7-6CFBA9D52803

Q33666297-7585E018-614F-44FA-A074-909E7E84F079

Q33666297-9522145E-B1B0-4F34-B9E8-5EA25541FDF9

Q33666297-9B2F98EB-5D4F-4200-BAC4-6995F3E73376

Q33666297-A36FF534-5381-40A0-934C-2F5579EEE775

P2860

Q33666297-029AE4FA-A11D-4C60-BF62-BE0062B7700C

Q33666297-08F1AD24-D1C7-41C3-8AB0-3217D1B2BD89

Q33666297-1358B9B5-0771-4FD7-B4C5-59691B8D85C7

Q33666297-1892F522-47C6-4800-84E5-AB566BE709C1

Q33666297-21275857-1F7B-451C-9F54-52D1EA05BCAA

Q33666297-2219D797-A140-4AF5-9768-7DCD2F544059

Q33666297-240F523F-B817-409F-B5A8-B8F6E1795515

Q33666297-2E448363-CB68-48DC-8867-6C1B35FC1B5C

Q33666297-2EB68FDF-8A59-4F86-8E29-84F4F7441C55

Q33666297-31D363C0-A72D-4946-9506-8EC9655E85D0

P304

Q33666297-F6E7D3D4-005E-47D1-B4E1-665D2303CA31

P31

Q33666297-C0B17CB1-29CA-4320-9E62-0C4BBFF4B09C

P356

Q33666297-6E69B64D-6A55-4244-8744-8CADB85124EE

P407

Q33666297-4B3BB1C9-9696-45B8-A548-1E07338B004C

P433

Q33666297-696B64C7-B6F0-41F2-803D-3AB974DE326E

P478

Q33666297-E1B721DD-8598-4C08-8AD9-FA55C8F3306C

P50

Q33666297-1B510860-F95D-4EA3-ACA5-EB9061B17651

Q33666297-354A4133-8926-4DD1-8014-C10814BC78E3

Q33666297-427B0D81-DF6F-43F0-BA03-902E63F4C210

Q33666297-7AB6E11E-C019-42B9-980F-5CAF04697DE5

Q33666297-7E85E550-20C9-434D-BB7D-E32761B00E0F

Q33666297-809470B4-B48F-4A7F-8EED-05BE7DB9D952

Q33666297-AA61B440-C1C5-4891-9A91-3A02B33B0A18

P577

Q33666297-FABC3EF5-60D0-48CB-AAC7-301A332B192A

P5875

Q33666297-732260BD-5AC1-4162-B570-4BB8CC5A9CA4

P698

Q33666297-2EF31199-9820-49DD-98A9-65E07AC349EE

P921

Q33666297-0C662D60-6B60-47C3-A748-8C1E11BB5BE9

Q33666297-9BF4F236-5E1C-4AE6-8188-2AA36C5E04E0

Q33666297-ADE5E1E8-4158-4949-8B15-EDC79345443B

P932

Q33666297-59B7C98D-F064-492F-9A0C-5472ADB19D87

P356

JAMANEUROL.2013.3861

P1433

P1476

Association of cerebrospinal f ...... with early Parkinson disease.

@en

P2093

Alice S Chen-Plotkin

http://www.w3.org/2001/XMLSchema#string

Chelsea Caspell

http://www.w3.org/2001/XMLSchema#string

Christopher S Coffey

http://www.w3.org/2001/XMLSchema#string

Danna Jennings

http://www.w3.org/2001/XMLSchema#string

David J Irwin

http://www.w3.org/2001/XMLSchema#string

Ju-Hee Kang

http://www.w3.org/2001/XMLSchema#string

Kenneth Marek

http://www.w3.org/2001/XMLSchema#string

Leslie M Shaw

http://www.w3.org/2001/XMLSchema#string

Mark Frasier

http://www.w3.org/2001/XMLSchema#string

Parkinson's Progression Markers Initiative

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people

Genome-wide association study reveals genetic risk underlying Parkinson's disease

Identification of novel proteins associated with both alpha-synuclein and DJ-1

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

Neuropathologic substrates of Parkinson disease dementia.

Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach.

A data-driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes.

Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.

alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356.

P304

1277-1287

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMANEUROL.2013.3861

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Brit Mollenhauer

Andrew Singleton

John Q. Trojanowski

Caroline M Tanner

Andrew Siderowf

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262044674

http://www.w3.org/2001/XMLSchema#string

P698

23979011

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

cerebrospinal fluid

P932

4034348

http://www.w3.org/2001/XMLSchema#string